Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.
Nguyen, D., Lemos, C., Wortmann, L., Eis, K., Holton, S.J., Boemer, U., Moosmayer, D., Eberspaecher, U., Weiske, J., Lechner, C., Prechtl, S., Suelzle, D., Siegel, F., Prinz, F., Lesche, R., Nicke, B., Nowak-Reppel, K., Himmel, H., Mumberg, D., von Nussbaum, F., Nising, C.F., Bauser, M., Haegebarth, A.(2019) J Med Chem 62: 928-940
- PubMed: 30563338 
- DOI: https://doi.org/10.1021/acs.jmedchem.8b01606
- Primary Citation of Related Structures:  
6HKM, 6HKN - PubMed Abstract: 
The availability of a chemical probe to study the role of a specific domain of a protein in a concentration- and time-dependent manner is of high value. Herein, we report the identification of a highly potent and selective ERK5 inhibitor BAY-885 by high-throughput screening and subsequent structure-based optimization. ERK5 is a key integrator of cellular signal transduction, and it has been shown to play a role in various cellular processes such as proliferation, differentiation, apoptosis, and cell survival. We could demonstrate that inhibition of ERK5 kinase and transcriptional activity with a small molecule did not translate into antiproliferative activity in different relevant cell models, which is in contrast to the results obtained by RNAi technology.
Organizational Affiliation: 
Research & Development, Pharmaceuticals , Bayer AG , 13353 Berlin , Germany.